Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 for Respiratory Infections in Elderly
NCT04435379Phase 3Completed
- Sponsor
- Serum Life Sciences
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and respiratory tract infection (RTI) comparing VPM1002 with Placebo (2 arms). Primary endpoint: Number of days with severe respiratory disease at hospital and/or at home. Started Jun 2020; status: completed.
02
Drugs
VPM1002
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT04435379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435379.